Angiotensin II receptor blocker prevents increased arterial stiffness in patients with essential hypertension

Circulation Journal

Volumn 68, Issue 12, 2004, Pages 1194-1198

  Agata, Jun ^a,d   Nagahara, Daigo ^a   Kinoshita, Shuichi ^b   Takagawa, Yoshitoki ^c   Moniwa, Norihito ^a   Yoshida, Daisuke ^a   Ura, Nobuyuki ^a   Shimamoto, Kazuaki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Tonan Hospital   (Japan)

^c Otaru City General Hospital   (Japan)

^d Sapporo General Hospital of Hokkaido Railway Company   (Japan)

Author keywords

Adiponectin; Angiotensin II receptor blocker; Hypertension; Pulse wave velocity

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; VALSARTAN;

ADULT; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; LONG TERM CARE; MALE; PULSE WAVE; TREATMENT OUTCOME;

ADIPONECTIN; ADRENERGIC ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; ELASTICITY; FEMALE; HUMANS; HYPERTENSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PULSE;

EID: 10944233185     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.1194     Document Type: Article

References (30)

1. Boutouyrie P, Isabelle A, Asmar R, Gatier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002; 39: 10-15.
2. Blacher J, Asmar R, Djane S, London G, Safar M. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: 1111-1117.
3. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
4. Tubakimori S, Motomura T, Kimura K. Experience in using form (ABI/PWVBP-203RPE) and comparison of form ABI/PWV and carotid vascular echogram (abstract). In 20th Vascular Non-Invasive Diagnostic Method Seminar, 2000 (in Japanese).
5. Nakamura U, Iwase M, Nohara S, Kanai H, Ichikawa K, Iida M. Usefulness of brachial-ankle pulse wave velocity measurement: Correlation with abdominal aortic calcification. Hypertens Res 2003; 26: 163-167.
6. Taniwaki H, Kanda H, Kawagishi T, Maekawa K, Emoto M, Nishizawa Y, et al. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Diabetes Care 1999; 22: 1851-1857.
7. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-325.
8. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
9. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289.
10. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703.
11. Nakano Y, Tobe T, Ohoi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo) 1996; 120: 803-812.
12. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
13. Oushi N, Kihara S, Akita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: Adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
14. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadipinectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
16. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
17. Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767-2770.
18. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, et al. Blockade of the rennin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
19. Shirakawa M. Estimation of organic atherosclerosis by pulse wave velocity. Tokyo Jikeikai Med J 1974; 89: 62-77 (in Japanese).
20. Amar J, Ruidavets JB, Chamontin B, Drouet L, Ferrieres J. Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens 2001; 19: 381-387.
21. Levy BI, Michel JB, Salzmann JL, Devissageut M, Safar ME. Remodeling of heart and arteries by chronic converting enzyme inhibition in spontaneously hypertensive rats. Am J Hypertens 1991; 4: 240S-245S.
22. Isobe N, Taniguchi K, Oshima S, Ono Z, Adachi H, Toyama T, et al. Candesartan cilexetil improves lift ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ J 2002; 66: 993-999.
23. Barra JG, Lavenson J, Armentano RL, Cabrera Fisher EI, Pichel RH, Simon A. In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Am J Physiol 1997; 27: H859-H868.
24. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611.
25. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARg ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099.
26. Togashi N, Ura N, Higashiura K, Murakami H, Shimamoto K. The contribution of skeletal muscle tumor necrosis factor-a to insulin resistance and hypertension in fructose-fed rats. J Hypertens 2000; 18: 1605-1610.
27. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-2767.
28. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen P, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaque instability. Circulation 2000; 101: 1372-1378.
29. Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J 2002; 66: 529-533.
30. Takada M, Ura N, Higashiura K, Murakami H, Togashi N, Shimamoto K. Effects of cilnidipine on muscle fiber composition, capillary density and muscle blood flow in fructose-fed rats. Hypertens Res 2001; 24: 565-572.